evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 6 findings · 2 reviews · Common Mental Disorders

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 5 · 83.3%High 0 · 0%

Intervention not reported

Sleep onset latency Participant reports. Scale from 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
  • Eszopiclone for insomnia 2018 · Cochrane Headline outcomes only
    no estimate extracted
    9 studies · 2890 participants
    Moderate

Intervention not reported

Wake time after sleep onset Participant reports. Scale from: 30 to 540 minutes; fewer minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
  • Eszopiclone for insomnia 2018 · Cochrane Headline outcomes only
    no estimate extracted
    8 studies · 2295 participants
    Moderate

Intervention not reported

Total sleep time Participant reports. Scale from: 300 to 840; more minutes equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review
  • Eszopiclone for insomnia 2018 · Cochrane Headline outcomes only
    no estimate extracted
    9 studies · 2935 participants
    Moderate

Intervention not reported

Next‐day alertness Participant reports. Scale from: 0 to 10 points; higher scores equalled better outcome; CFB and double‐blind average values included · Patients with insomnia
1 finding from 1 review

Intervention not reported

Serious adverse events (as defined in the primary study) Participant reports. Serious adverse events observed during double‐blind treatment period · Patients with insomnia
1 finding from 1 review
  • Eszopiclone for insomnia 2018 · Cochrane Headline outcomes only
    no estimate extracted
    12 studies · 4289 participants
    Moderate

COMPARISON 1. ARIPIPRAZOLE vs placebo

Numbers completing double‐blind treatment Number of participants · patients with an acute manic or mixed episode

Aripiprazole showed no clear difference in numbers completing double‐blind treatment Number of participants compared with placebo (moderate certainty).

1 finding from 1 review